Tag Archive | "Daiichi Sankyo"

Daiichi Sankyo: Company Profile

Tags: ,

Return to top 50 pharma list


Website: Daiichi

Headquarters: Tokyo, Japan

Ticker:  D4S (Frankfurt Stock Exchange)

SEC: Daiichi Sankyo

Recent deal news: Daiichi Sankyo deal news at Current Partnering

Must read report: Partnering Deals and Alliances with Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan.

Daiichi Sankyo Co. Ltd. was established in 2005 with the merger of two leading century-old pharmaceutical companies, Daiichi Pharmaceutical and Sankyo.

Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

Daiichi Sankyo maintains a portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections around the world and also focuses on the discovery of novel oncology therapies.

The company strives to accomplish its vision by acquiring new product candidates, new products and/or companies that will drive its portfolio in key therapeutic categories. It  is actively engaged in continuously improving its R&D processes for medicines in:

  • Oncology
  • Cardiovascular and Metabolic Disorders
  • “Frontier” – innovative discoveries in a variety of mechanisms and diseases

Daiichi Sankyo has an active licensing venture investment and acquisition group charged with analysing and managing all incoming opportunities more

Daiichi Sankyo announced over 47 partnering / licensing deals since its inception in 2005, with atleast 10 deals in 2011 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in cardiovascular, cancer, followed by infectives and metabolic diseases more

Daiichi Sankyo has also announced 5 M&A deals since 2005, with the lead deals being the acquisition of Plexxikon, Zenotech and Ranbaxy Laboratories more

Top 50 pharma ranking*: 24

*based on reported global sale for year ending December 2013.

Key financials

Total annual revenue

Daiichi annual revenues

Total annual R&D spend

Daiichi R and R spend

Top selling drugs

Daiichi Top Drug Sales


Daiichi Sankyo partnering interests

Daiichi Sankyo partnering activity

Daiichi Sankyo M&A activity


Available reports from Current Partnering

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Daiichi Sankyo


Available resources for deal coverage for Daiichi Sankyo

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Daiichi Sankyo company profile, recent partnering, M&A and financing news and articles



Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

return to top 50 pharma list


Big pharma alliances for infectious diseases drug development

Tags: , , , , , ,

Five Japanese life sciences giants pharma alliances with the Bill and Melinda Gates Foundation and Japan’s government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries. Read the full story

Daiichi & Amplimmune announce biotech partnering

Tags: , , ,

Daiichi Sankyo, a big pharma company, and Amplimmune have entered into a broad strategic biotech partnering to develop a new therapeutic protein, AMP-110.   Read the full story

Partnering Agreements with Daiichi Sankyo

Tags: , , , , , ,

This report provides all the information you require to better understand Daiichi Sankyo and its partnering interests and activities over the past seven years. Read the full story

Daiichi signs pharma alliances deal with Coherus for biosimilars

Tags: , , ,

Daiichi Sankyo, a top big pharma company announced the execution of an exclusive pharma alliances agreement with Coherus BioSciences to develop and commercialize biosimilar forms of etanercept and rituximab in certain Asian countries including Japan Read the full story

CMC Biologics announces agreement with Daiichi Sankyo to develop and manufacture antibodies

Tags: , ,

Agreement with Daiichi Sankyo to provide process development support and manufacture of several clinical-stage antibodies over a three-year period.  Read the full story

Bigpharma increases activity in China

Tags: , , , , , , , , , , , , ,

The start of 2011 has seen some significant deal activity involving Bigpharma in China. Read the full story

Current Agreements Deals Update – April 2011

Tags: , , , , , , , , , , ,

Welcome to the April 2011 edition of Current Agreements Deals Update.  Read the full story

Pfizer and Daiichi Sankyo team up in China

Tags: , , , ,

Pfizer has agreed to promote a hypertension drug from Daiichi Sankyo Pharma in China.  Read the full story

Daiichi Sankyo acquires Plexxikon in a $935 million deal

Tags: , , ,

Hot on the heals of Plexxikon announcing positive interim data from a Phase III trial evaluating its lead oncology candidate, PLX4032 Read the full story